期刊
EXPERT OPINION ON DRUG DELIVERY
卷 18, 期 10, 页码 1335-1354出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425247.2021.1919619
关键词
Tretinoin; all-trans retinoic acid; nanotechnology; cancer; acute promyelocytic leukemia; drug delivery; self-assembly; drug combination; nano-conjugates
资金
- CAPES
- CNPq
- FAPEMIG
All-trans retinoic acid (ATRA) is effective in treating acute promyelocytic leukemia (APL) but less so in other types of cancer. Nanotechnology shows promise in enhancing ATRA's anticancer activities and overcoming its limitations, such as bioavailability and resistance issues.
Introduction: All-trans retinoic acid (ATRA, tretinoin) is the main drug used in the treatment of acute promyelocytic leukemia (APL). Despite its impressive activity against APL, the same could not be clinically observed in other types of cancer. Nanotechnology can be a tool to enhance ATRA anticancer efficacy and resolve its drawbacks in APL as well as in other malignancies. Areas covered: This review covers ATRA use in APL and non-APL cancers, the problems that were found in ATRA therapy and how nanoencapsulation can aid to circumvent them. Pre-clinical results obtained with nanoencapsulated ATRA are shown as well as the two ATRA products based on nanotechnology that were clinically tested: ATRA-IV (R) and Apealea (R). Expert opinion: ATRA presents interesting properties to be used in anticancer therapy with a notorious differentiation and antimetastatic activity. Bioavailability and resistance limitations impair the use of ATRA in non-APL cancers. Nanotechnology can circumvent these issues and provide tools to enhance its anticancer activities, such as co-loading of multiple drug and active targeting to tumor site.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据